@entity1499 , XXXX , @entity1260 , and @entity900 in poor-risk nonseminomatous @entity2971 .

@entity1 @entity8 @entity82 @entity137 @entity1261 @entity12962 @entity2971 @entity39 @entity16 @entity900 @entity1311 @entity2359 @entity1503 @entity1398 @entity1260 @entity1499 @entity44
OBJECTIVE: The efficacy and tolerability of M-TIP was evaluated as first-line treatment for @entity1 with poor-risk @entity2971 ( @entity2971 ), according to International Germ Cell Cancer Collaborative Group (IGCCCG) criteria. @entity1 AND METHODS: Thirty @entity1 with poor-risk @entity2971 were treated with M-TIP ( @entity1499 250 mg/m(2) given as a 4-hour infusion with folinic acid rescue on day 1, @entity1311 175 mg/m(2) given as a 3-hour infusion on day 1, followed by @entity1260 1.2 g/m(2) given as a 2-hour infusion and @entity900 20 mg/m(2) given as a 2-hour infusion on days 2 to 6) regimen for four cycles. RESULTS: Five (16.6%, 95% confidence interval [CI]: 2%-31%) @entity1 achieved clinical complete response (cCR) with chemotherapy only, 15 (50%, 95% CI: 31-69%) @entity1 pathologic complete response (pCR) (11 had @entity39 / @entity82 and 4 had mature @entity44 ) and 3 (10%) @entity1 surgical complete response (sCR) for an overall favorable response of 76.6%. Twenty-one @entity1 are continuously disease-free at a median follow-up of 5.3 years (range 0.9-8.4+ years), resulting in a 5-year progression-free survival (PFS) rate of 66.6% (95% CI = 49%-85%) and a 5-year survival rate of 70% (95% CI = 53%-87%). @entity137 was generally mild except for myelotoxicity. @entity1 with @entity1398 were successfully treated with broad spectrum antibiotics and @entity1261 support. @entity1503 in this trial was ameliorated with the use of @entity1261 . @entity2359 and nephrotoxicity were not a problem, since only 6.6% and 3.3% of @entity1 developed @entity16 and @entity8 , respectively. CONCLUSION: M-TIP is a highly effective (high proportion of @entity1 achieved long-term disease-free status, lack of relapses) and well tolerated regimen for first-line treatment of poor-risk @entity2971 @entity1 . These results have to be compared with the standard @entity12962 chemotherapy or more intensive regimens in multicentre randomized trials.
